To complement excellence in scientific research, successful commercialisation requires research teams to have a strong understanding of their target markets, the specific problems their technologies address, the competitive landscape, and the ability to...
Small Molecule Platform for Resistant Cancers
Novel platform targeting aggressive and highly resistant cancers with small molecule combinations that can synergise to deliver superior treatment performance at lower toxicities. In silico simulations will be...
Lead: Prof. Boris Kholodenko, Prof. Oleksii Rukhlenko
